Accumulated quality-adjusted life years gained, cost, and cost-effectiveness of selected scenarios.

<p>Accumulated quality-adjusted life years gained, cost, and cost-effectiveness of selected scenarios.</p

Parameter values for cost-effectiveness analysis.

<p>Parameter values for cost-effectiveness analysis.</p

Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men - Fig 1

<p><b>a-b: Incremental cost-effectiveness of PrEP (cost per QALY gained in thousands of US$)</b> *Combines drug cost, physician visits, and laboratory testing: drug cost:$10711/year, cost of physician visits: $1035/year, cost of renal function test:$30/year, cost of HIV testing: $108/year ^†Drug cost:$10711/year ^‡Drug cost: $6427/year ^§Drug cost:$4284/year ^‖Drug cost: 2142/year ^#Dominated refers to cost-effectiveness scenarios with higher cost and worse outcomes. c-d: PrEP drug cost stratified by cost per QALY threshold. *Current drug cost estimated at 10711.</p

One-way sensitivity analysis of PrEP cost-effectiveness (in US$).

<p>The black vertical line represents the base case-scenario relative to no PrEP ($64,000 per QALY gained). Blue bars represent the low value of the range, and red bars represent the high value of the range. Bars to the left of the base case scenario represent more favorable scenarios. Only parameters which affected the cost-effectiveness ratio by more than 50% in either direction are shown.</p